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reported (or Feldene exceeds that reported to the System for benoxa-
profen (Oraflex), a structurally unrelated nonsteroidal antiinflam-
matory agent that has been withdrawn from the market. The origi-
nal package insert for Feldene does not list photosensitivity as an 
adverse reaction associated with its use. Yet 29 of 36 reactions asso-
( iated with this drug were clinically ((insistent with photosensitivity 
reactions, and 2 of the remaining 7 reports of reactions were highly 
suggestive of exacerbation by exposure to sunlight. The 29 patients 
who had photosensitive eruptions (lb men and 13 women) ranged 
in age from 20 to 74 years; one patient (a man) was black. In 19 of 
the 29 patients the eruption occurred within four days and after 
llieii first sun exposure after the initiation of Feldene therapy. A 
majority of the cases included vesicles or bullae in sun-exposed 
Ninas. Pruritus was frequently associated with the eruption. 
The prompt onset of the eruption in relation to initial treatment 
and sun exposure suggests a pholotoxic rather than a pholoallcrgic 
reai lion. I line patients who had used thiazide diuretics for ex-
tended-periods ol time experienced photosensitivity reactions after 
feldene was added to their therapeutic regimens, suggesting pos-
sible additive or synergistic phOtOlOxie elicits of feldene and 
thiazides. 
Huston, MA 0221 5 
ROBER'I S. Si I-KN. Mi) 
Beth Israel Hospital 
flic above letter was referred 10 Phzei Laboratories, manufactur-
ers ol feldene, who oiler the lollow nig reply: 
I a Ike I'.dilo!: Although Dr. Stern correctly notes thai the original 
feldene (piroxicam) package insert did not list photosensitivity re-
actions, thev were added in August 1982, three months before we 
received a communication from him. We made this change vOiun-
l Miily because we had received reports of such reactions (including 
cases bom Dr. .Stein) alter feldene was introduced, even though we 
had iifil seen them in more than 1000 patients studied in our con 
trolled clinical trial*. We believe thai our current labeling, which 
stales that these read ions occur m fewer (ban 1 per cent of patient!, 
is supported by tins experience. 
Some government agencies, such as the Cou'imittce on Safety of 
.Medicines m the United Kingdom and the Swedish Regulator) 
Authority, routinely report information on advene reactions. Data 
bom llnse agencies suggcW that the incidence of phOtOICtUtlivil) 
reactions with Feldene is probably on the same order ol magnitude 
as (In incidence with olhei marketed nonsteroidal antiinflammatory 
dings, including ibupiolni, mdomriharui, and .naproxen 
Ph/ri has recently reviewed side efleCti in over 70,000 patients 
mound the win Id wl)0 were Heated will I'rldriit\xix well as m COftl 
paialiw Studies with mdi anel hai in and napioxrii I >r'i mat, llogK 
icai lions of anv kind o'ciuicd m about I to 3 per cent ol palicnts 
and had a sunilai u>< idence with each ol the drugs. 
Finally, it Shook) be itoted dial benoxnpijulcu was witlnbawii 
from iltc market because ol hepatic and rsrtal toxicity, not because 
ol photosensitivity, as implied ill Di Nteni't lillfi 
New York, NY Kiui 1 
KIM,IH S/M.MS. M I ) 
I'fr/ei I .abot atoi irx 
IRRI I AHII.I I V IN AU I LSI IC CHILDREN I HI,A I I-1*> 
Wl I II I FNI FCRAMINI. 
Tu III' tidiloi A icpi'M In (teller et al, presented pit'hnnn.ii \ 
results siiui/esinig j|ie possible iiselulness Of (enfluiamine (a subsli-
luted pliruv let h\ lariunr vs it Ir I \ used as all ap|»elile tinppi rssatil I m 
lite it i ai men I of infantile autism (July 15, I 982, issue) I lie i a ton 
ale ("i the use Of tljll agent rGstl on ill ability to lowei peripheial 
blond levels ol seioioniii and on die olnri v alion dial a <uibslanl ial 
iniflOriiy of̂ HUlillit prtx-onx have elevated peripheral hlOotl KTQ 
loiuii levelfC I he report emphasized the prehminaiv tiatute of the 
result* in a small sgiuple of three vouug aulistii bOVI With elcvaled 
i loioihii level* We have seen two our! m wltit li autistic t hildren 
writ In Iliad vx 11! i I Ins agent ,oid appealed to have advene icai lioiu 
to it. In neither ease was peripheral serotonin measured before 
treatment. 
A seven-year-old boy had been diagnosed as autistic al the age of 
five. I he child had a variety ofj.he features typical of autistic chil-
dren and was enrolled in a special-education program. His pediatri-
cian had given him fenfluramine. 10 nig four times a day,, During 
one month of treatment'with this agent the child became progres-
sively irritable and fearful. His activity level increased as his 
appetite decreased. Sleep was also disrupted. He deteriorated be-
haviorallv. and his family discontinued the medication. At our 
examination, performed two months after treatment had been 
stopped, his serotonin levels were not elevated (152 ng per milli-
liter)." 
An 1 1-year-old autistic bov had been started on fenfluramine (10 
mg four times a day) by his father, who had read the preliminary' 
report by Gellcr et al Serotonin levels were not determined before 
treatment. Over several days of treatment the child became more 
irritable and agitated. Fenfluramine was discontinued. The box's 
activity level was markedly increased during the time of treatment, 
and his father sought an evaluation. At oui examination, one month 
alter treatment had been discontinued, the child had a serotonin 
level of 2 I 2 ng per milliliter. 
Adverse reactions to fenfluramine have been noted previously. 
In one double-blind investigation the elluacv of this agent as an 
appetite suppressant was evaluated; both patients and phvsuians 
were able lo identify the a< live agent Correctly in over 70 pel cent of 
Cases largely on the basis ol side eHect.1 
There is no rationale lot the use "I fenfluramine in autistic chil-
dren who do not have elevated levels of serotonin furthermore, its 
efficacy m this population remains to be clearly established. Physi-
cians should lie aware ol possible adverse effects ol this agent in 
autistic Children and its investigational nature 
FRI i) K. VUI.KMAR. M D 
KIIKS I'M I . Pn I) 
DoNM „ J Coins, M I) 
I l i w i ii A SIIAVWIT/, M I) 
Vale I. niverxuv 
New Haven, CT065IO Child Sludv CcBfCI 
I Gellci F. RitvoBR, freeman HJ. Yuwiler A. Preliminary observations or. the 
effect of fenfluramine on blood serotonin and symptoms in throe autistic 
boyi N l-.ngl I Med l<«2; 307:163 9 
? Hartley HO. Stahl SM. Frccdman DX Hyperserotoncnna and amine metabo-
lite* in autistic and retarded children Aich (ien I'svxhiatrv 1977; 341521-J) 
3 Vclin J(.', Temple AH Fenfluramine p«i*9*»lng I I'ediait lx»75. 87:1 I" 
4 Brown*ll KD, Stunkard AJ The ikmbteblind in danger untoward suns, 
qtieines ol informed sonvrw Am I ISvyhiativ |U>C. 1 W |4H7 W 
( IMFFIDIM, WD I'()| Y .Vivos I I IS 
To ihf I'.fiuoi Watson et al recently reported a case of poiyniyosi 
tis induced by cimciidinc, a drug with a possible role as an immune-
modulator ( |an 20 issue) ! Sun e Novernbei 1982, WC have had the 
uppottunil v lo lollow (lie patieul described hi then report and wish 
lo prov iile lollow up data thai .o gur ac.i mst I he i "!<- ol < nun icbue in 
inducing polymyositis in t|\is patient. 
Although ci | net nil ne had been dis, oniinued m |anu.u \ I '*H'.' ihr 
patient had active myositis when first seen },>• us fo January IUH-, 
while taking prednisone (60 fflfi pet day) and njen aptopui me (SO 
ma tliife tiinex a day), he had a severe e,xacerbatii>n ol myosins 
ih profound weakness and elevation ol kinai .'K'l.OI Nl 
II pet hlei He denied uxinji i unci aluir oi ,,|i ohol Sun < iheu his 
myositis has irmaiueil BCttvt despite lie.ument with hitdi ,|. 
piednisoiir and methotrexate 
It is appareni thai l '< months alter diseoniinuaiiofl oi, irrn?lidinft, 
this [latietu lontimiex to have progressivt polymyositis t*hl 
'hatplv wnil |ue\lonsK reported eases of drug induced polv 
myositis, in which remission of diseast was oljuerved WK>H aAet 
ilisi onimiiation of the thug Kot example, in all previous)) rtSK»rted 
, ,oi • of peine illamnti axsoi i ft ted (Vols mvosius rerllisStl HI ot I too kl '' 
impiovement in hoil, ihtu.al and labm .< lot w teBinies ol rnvositi-
o,, in ied within six months o( stopping the drug In no cww 
